Patients With Intermediate Stage HCC Suitable for TACE

Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.

Related Videos
In this second episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, explain the evolution of minimally invasive surgery and the emergence of interventional radiology in gastrointestinal cancer.
Christos Fountzilas, MD, FACP
Expert on breast cancer
Experts on BTC
Experts on BTC
In this first episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, discuss the importance of endoscopic oncology as it relates to rising cancer incidence and multidisciplinary care in gastrointestinal cancer.
Expert on CSCC
Experts on CSCC
James Harding, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center
Experts on AML
Related Content

Investigators Struggle to Understand Causes Behind Growth of Appendix Cancer

March 16th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors

March 13th 2023

Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

December 12th 2022

State of Science Summit- GI Cancers: Chaired by Jimmy Hwang, MD

March 9th 2023

FDA Grants Orphan Drug Designation to YB-200 for Hepatocellular Carcinoma

March 1st 2023

Investigators Struggle to Understand Causes Behind Growth of Appendix Cancer

March 16th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors

March 13th 2023

Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

December 12th 2022

State of Science Summit- GI Cancers: Chaired by Jimmy Hwang, MD

March 9th 2023

FDA Grants Orphan Drug Designation to YB-200 for Hepatocellular Carcinoma

March 1st 2023

Investigators Struggle to Understand Causes Behind Growth of Appendix Cancer

March 16th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors

March 13th 2023

Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent

December 12th 2022

State of Science Summit- GI Cancers: Chaired by Jimmy Hwang, MD

March 9th 2023

FDA Grants Orphan Drug Designation to YB-200 for Hepatocellular Carcinoma

March 1st 2023